WO2006097458A1 - Nouvelle combinaison - Google Patents

Nouvelle combinaison Download PDF

Info

Publication number
WO2006097458A1
WO2006097458A1 PCT/EP2006/060682 EP2006060682W WO2006097458A1 WO 2006097458 A1 WO2006097458 A1 WO 2006097458A1 EP 2006060682 W EP2006060682 W EP 2006060682W WO 2006097458 A1 WO2006097458 A1 WO 2006097458A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
ciclesonide
olopatadine
mucosa
application
Prior art date
Application number
PCT/EP2006/060682
Other languages
English (en)
Inventor
Helgert MÜLLER
Mark W. Salyer
Original Assignee
Nycomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh
Publication of WO2006097458A1 publication Critical patent/WO2006097458A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Definitions

  • the present invention is related to a novel combination of ciclesonide and olopatadine for use in drug therapy in particular in the treatment of allergic rhinitis.
  • the novel combination is administered in the form of an aqueous pharmaceutical composition that contains ciclesonide and olopatadine and having an osmotic pressure of less than 290 mOsm.
  • Allergic rhinitis is a common disorder and the number of patients is steadily increasing.
  • the disease is caused by ambient airborne allergens, which cause an allergic inflammation within the nasal mucosa and it is often accompanied by conjunctivitis.
  • the allergic rhinitis is subdivided into seasonal allergic rhinitis (allergens like grass pollen, cedar pollen) and perennial allergic rhinitis (indoor allergens like mould, allergens from animals and house dust mite).
  • Allergic rhinitis has a great impact on the quality of life.
  • the patients suffer from an itchy and running nose, nasal blockage, headache and fatigue.
  • Allergic conjunctivitis is often linked to allergic rhinitis and requires co- treatment.
  • the major symptoms of conjunctivitis are burning and itching eyes and lacrimation.
  • the basic mechanisms involved in this disease are the same as for allergic rhinitis.
  • the allergens cause an eosinophilic inflammation of the nasal mucosa, which is mainly responsible for symptoms like nasal hyperreactivity, nasal blockage and the fear of the so called change of floors, which means that an untreated allergic rhinitis can develop to sinusitis and asthma bronchiale.
  • glucocorticoids Treatment with glucocorticoids is currently the only one therapy, which targets the underlying allergic inflammation.
  • topical treatment with glucocorticoids is the preferred way of administration.
  • a disadvantage of nasal steroids is the slow onset of action and the need for continuous treatment. It takes 4-6 days of continuous treatment before a symptom relief can be observed. Therefore, the pa- tients are recommended to begin to take glucocorticoids before the pollen season starts. The slow onset of action, the need of consequent treatment and the fear of steroid induced side effects have a negative impact on the use of intranasal steroids and patient's compliance.
  • intranasal muscarinic antagonists ipratropium to reduce nasal secretion
  • adrenoreceptor agonists xylometha- zoline to reduce nasal congestion
  • WO 97/01337 describes a nasal spray or nasal drops formulation comprising beclomethasone, fluni- solide, triamcinolone, dexamethasone or budesonide in combination with the antihistamines levoca- bastine, azelastine or azatadine and sterile water.
  • WO 97/46243 is related to a nasal spray containing an intranasal steroid and an antihistamine.
  • WO 98/48839 is related to topically applicable nasal compositions comprising a therapeutically effective amount of an antiinflammatory agent and a therapeutically effective amount of at least one agent selected from the group consisting of a vasoconstrictor, a neuraminidase inhibitor, a leukotriene inhibitor, an antihistamine, an antiallergic agent, an anticholinergic agent, an anesthetic and a mucolytic agent.
  • WO 01/22955 is related to a novel combination of loteprednol, a so-called soft steroid with antihistamines.
  • WO 03/049770 discloses compositions and methods for treating rhinitis with H1 antago- nists/antiallergics and safe steroids. Inter alia olopatadine is mentioned as useful H1 antagonist/antiallergic.
  • WO 2004/043470 is related to compositions and methods for treating rhinitis with certain combinations of antiallergic agents and steroids.
  • the anti-allergy agent is selected to be emedastine or olopatadine.
  • the steroid is selected to be fluticasone, mometasone, budesonide or beclomethasone.
  • US 5164194 is related to nasal formulations for azelastine.
  • US 2003/0055102 is related to topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the eye and nose.
  • WO 2004/019955 is related to a combination of ciclesonide with antihistamines.
  • the present invention therefore relates to the combined administration of ciclesonide and olopatadine for the treatment of allergic rhinitis and/or allergic conjunctivitis.
  • Another subject of the invention therefore is a pharmaceutical composition for the treatment of allergic rhinitis and/or allergic conjunctivitis comprising as active ingredients a combination of olopatadine or a pharmaceutically acceptable salt and/or a solvate or physiologically functional derivative thereof and ciclesonide, pharmaceutically acceptable salts of ciclesonide, epimers of ciclesonide in any mixing ratio with ciclesonide, solvates of ciclesonide, physiologically functional derivatives of ciclesonide or solvates thereof and a pharmaceutically acceptable carrier and/or one or more excipients.
  • both drugs may be provided separately as oral formulations, or one may be an oral preparation and the other an inhalant, or both may be provided in a form suitable for application to mucosa (nasal application).
  • Administration may be at the same time. Or they may be administered either close in time or remotely, such as where one drug is administered in the morning and the second drug is administered in the evening.
  • the present invention also provides a method for the prophylaxis or treatment of allergic rhinitis and/or allergic conjunctivitis in a mammal, such as a human, which comprises administration of a therapeutically effective amount of a pharmaceutical formulation comprising olopatadine or a pharmaceutical acceptable salt, solvate, or physiologically functional derivative thereof and ciclesonide or a pharmaceutical acceptable salt, solvate, or physiologically functional derivative thereof, and a pharmaceutical acceptable carrier and/or one or more excipients.
  • a method which comprises administration of a therapeutically effective amount of a combination comprising olopatadine and ciclesonide, and a pharmaceutical acceptable carrier and/or one or more excipients.
  • the formulations include those suitable for oral, parenteral including subcutaneous, intradermal, intramuscular, intravenous and intraarticular, intranasal, inhalation (including fine particle dusts or mists which may be generated by means of various types of metered dose pressurised aerosols, nebulisers or insufflators), rectal and topical (including dermal, buccal, sublingual and intraocular administration) although the most suitable route may depend upon for example the condition and disorder of the recipient.
  • the formulation is suitable for topical administration.
  • the formulation according to the invention is a formulation suitable for application to mucosa in the case of treatment of allergic rhinitis.
  • a preferred formulation is a formulation suitable for conjunctival administration (application to the conjunctival sac).
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredients into association with the carrier, which constitutes one or more accessory ingredients/excipients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
  • Formulations for nasal administration also include powder compositions, which can contain reducing sugars such as lactose as carrieres, and spray compositions which may be formulated, for example, as aqueous solutions or suspensions or as aerosols delivered from pressurised packs, with the use of a suitable propellant, e. g. 1 , 1 , 1 , 2-tetrafluorethane, 1 , 1 , 1 , 2, 3, 3, 3-heptafluoropropane, carbon dioxide or other suitable gas.
  • a suitable propellant e. g. 1 , 1 , 1 , 2-tetrafluorethane, 1 , 1 , 1 , 2, 3, 3, 3-heptafluoropropane, carbon dioxide or other suitable gas.
  • a class of propellants which are believed to have minimal ozone- depleting effects in comparison to conventional chlorofluorocarbons comprise hydrofluorocarbons and a number of medicinal aerosol formulations using such propellant systems are disclosed in, for example, EP 0372777, W091/04011 , W091/11173, W091/11495, W091/14422, W093/11743, and EP- 0553298. These applications are all concerned with the preparation of pressurised aerosols for the administration of medicaments and seek to overcome problems associated with the use of this new class of propellants, in particular the problems of stability associated with the pharmaceutical formulations prepared.
  • the applications propose, for example, the addition of one or more of excipients such as polar cosolvents or wetting agents (e.g. alcohols such as ethanol), alkanes, dimethyl ether, surfactants (including fluorinated and non-fluorinated surfactants, carboxylic acids such as oleic acid, poly- ethoxylates etc.) or bulking agents such as a sugar (see for example WO02/30394) and amino acids and vehicles such as cromoglicic acid and/or nedocromil which are contained at concentrations, which are not therapeutically and prophylactically active (see WO00/07567).
  • excipients such as polar cosolvents or wetting agents (e.g. alcohols such as ethanol), alkanes, dimethyl ether, surfactants (including fluorinated and non-fluorinated surfactants, carboxylic acids such as oleic acid, poly- ethoxylates etc.) or bulking agents such as
  • the active ingredients should be micronised so as to permit inhalation of substantially all of the active ingredients into the lungs upon administration of the aerosol formulation, thus the active ingredients will have a mean particle size of less than 100 microns, desirably less than 20 microns, and preferably in the range 0.7 to 10 microns, for example, 1 to 5 microns.
  • a suitable formulation for ciclesonide based on hydrofluorocarbon propellants is for example known from U.S. Patent 6,120,752.
  • U.S. Patent 6,120,752 discloses and claims, inter alia, pharmaceutical compositions comprising a therapeutically effective amount of ciclesonide or a related compound and a hydrofluorocarbon propellant, preferably selected from 1 ,1 ,1 ,2-tetrafluoroethane, 1 ,1 ,1 ,2,3,3,3- heptafluoropropane and a mixture thereof, and cosolvent, preferably ethanol, in an amount effective to solubilize ciclesonide and optionally a surfactant.
  • the present invention therefore also relates to pharmaceutical compositions for treatment of allergic rhinitis, which comprise a propellant selected from 1 ,1 ,1 ,2-tetrafluoroethane, 1 ,1 ,1 ,2,3,3,3-heptafluoropropane and mixtures thereof.
  • a propellant selected from 1 ,1 ,1 ,2-tetrafluoroethane, 1 ,1 ,1 ,2,3,3,3-heptafluoropropane and mixtures thereof.
  • the pharmaceutical compositions may additionally comprise a surfactant and/or ethanol.
  • the pharmaceutical composition preferably is for nasal administration.
  • Canisters generally comprise a container capable of withstanding the vapour pressure of the propellant, such as plastic or plastic-coated glass bottle or a metal can, for example an aluminium can which may optionally be anodised, lacquer-coated and/or plastic-coated, which container is closed with a metering valve.
  • Canisters may be coated with a fluorocarbon polymer as described in WO 96/32150, for example, a co-polymer of polyethersulphone (PES) and polytetrafluoroethylene (PTFE). Another polymer for coating that may be contemplated is FEP (fluorinated ethylene propylene).
  • PES polyethersulphone
  • PTFE polytetrafluoroethylene
  • the metering valves are designed to deliver a metered amount of the formulation per actuation and incorporate a gasket to prevent leakage of propellant through the valve.
  • the gasket may comprise any suitable elastomeric material such as for example low density polyethylene, chlorobutyl, black and white butadiene-acrylonitrile rubbers, butyl rubber and neoprene.
  • Thermoplastic elastomer valves as described in W092/11190 and valves containing EPDM rubber as described in W095/02650 may be suitable. Suitable valves are commercially available from manufacturers well known in the aerosol industry, for example, from Valois, France (eg. DF10, DF30, DF60), Bespak pic, UK (eg. BK300, BK356, BK357) and 3M-Neotechnic Ltd, UK (eg. Spraymiser).
  • Valve seals especially the gasket seal and also the seals around the metering chamber, can be manufactured of a material, which is inert to and resists extraction into the contents of the formulation, especially when the contents include ethanol.
  • Valve materials especially the material of manufacture of the metering chamber, can be manufactured of a material which is inert to and resists distortion by contents of the formulation, especially when the contents include ethanol.
  • Particularly suitable materials for use in manufacture of the metering chamber include polyesters eg polybutyleneterephthalate (PBT) and acetals, especially PBT.
  • Materials of manufacture of the metering chamber and/or the valve stem may desirably be fluorinated, partially fluorinated or impregnated with fluorine containing substances in order to resist drug deposition.
  • Valves which are entirely or substantially composed of metal components (eg Spraymiser, 3M- Neotechnic), are especially preferred for use according to the invention.
  • the medical product based on aerosol formulations preferably has a nasal actuator.
  • the present invention relates to an aqueous pharmaceutical composition for the treatment of allergic rhinitis for application to the mucosa, comprising as active ingredients a combination of olopatadine and ciclesonide.
  • the present invention further relates to an aqueous pharmaceutical composition for the treatment of allergic rhinitis for application to the mucosa comprising as active ingredients a combination of olopatadine and ciclesonide together with one or more water-insoluble and/or water-low soluble substance and having an osmotic pressure of less than 290 mOsm.
  • the osmotic pressure is 150 mOsm or lower, more preferably 75 mOsm or lower, more preferably 50 mOsm or lower.
  • a substance for controlling osmotic pressure osmotic pressure-controlling agent
  • any substance can be used.
  • a substance for controlling osmotic pressure osmotic pressure controlling agent
  • can be added to control osmotic pressure specific examples of which include salts such as sodium chloride and water-soluble sugars such as glucose, with glucose being a particularly preferable example.
  • the pharmaceutical composition is a pharmaceutical composition as described for ciclesonide in WO 01/28562 or WO 01/28563.
  • the present invention relates to an aqueous pharmaceutical composition for the treatment of allergic rhinitis for application to the mucosa, comprising as active ingredients a combination of olopatadine and ciclesonide together with one or more water-insoluble and/or water-low soluble substance and having an osmotic pressure of less than 290 mOsm.
  • the water-insoluble or water-low soluble substance may be any substance, and preferred examples include celluloses, more preferably crystalline celluloses and particularly preferred microcrystalline celluloses.
  • the concentration of water-insoluble and/or water-low soluble substance present in form of solid particles in an aqueous medium is preferably 0.3% w/w and above, and particularly preferably 0.5% w/w to 5% w/w, relative to the total amount of the composition.
  • an aqueous polymer substance can also be added in the present pharmaceutical composition.
  • aqueous polymer substance can also be added in the present pharmaceutical composition.
  • specific examples of such include polyvinylpyrrolidone, propylene glycol alginate, pectin, low methoxyl pectin, gua gum, gum Arabic, carrageenan, methyl cellulose, carboxymethyl cellulose sodium, xanthan gum hydroxypropylmethyl cellulose and hydroxypropyl cellulose, while particularly preferable examples include carboxymethyl cellulose sodium, polyethylene glycol and hydroxypropyl cellulose.
  • Carboxymethyl cellulose sodium blended with microcrystalline cellulose is an example of a combination of these water-soluble substance and water-insoluble substance that can be used in the present invention.
  • the concentration of said substance is preferably 1 % w/w to 30 % w/w relative to the water-insoluble substance and/or water-low soluble substance.
  • hydroxypropylmethyl cellulose is contained in the pharmaceutical compositions according to the invention.
  • the hydroxypropylmethyl cellulose may be any grade, a specific example is hydroxypropylmethyl cellulose 2910. Although said hydroxypropylmethyl cellulose may be present at any concentration, its concentration is preferably from 0.001 % w/w to 30 % w/w, particularly preferably form 0.01 % w/w to 5 % w/w, more particularly preferably from 0.01 % w/w to 1 % w/w, and most preferably from 0.01 % w/w to 0.5 % w/w, relative to the total amount of composition.
  • a surfactant and/or wetting agent although not essential in the present invention, can be added, specific examples of which include Polysorbate 80, glycerin monosterarate, polyoxyl stearate, lauro- macrogol, sorbitan oleate and sucrose fatty acid esters.
  • An effective amount of ciclesonide and olopatadine used in the present invention can be determined according to the type and degree of the respective disease, as well as the age and body weight of the patient, and so forth.
  • the pharmaceutical composition according to the invention is administered as one to four sprays per nostril once or twice a day.
  • the dose of ciclesonide per actuation is expediently from 10 ⁇ g to 400 ⁇ g, preferably 20 ⁇ g to 200 ⁇ g.
  • the dose of olopatadine is from 50 ⁇ g to 1000 ⁇ g, preferably 100 ⁇ g to 800 ⁇ g per actuation.
  • Ciclesonide (hereinafter also referred to as active ingredient) is the INN for a compound with the chemical name [11 ⁇ , 16 ⁇ (R)]-16, 17-[(Cyclohexylmethylen)bis(oxy)]-11 -hydroxy-21 -(2-methyl-1 -oxoprop- oxy)pregna-1 ,4-dien-3,20-dion. Ciclesonide and its preparation are disclosed in DE 4129535. Ciclesonide as used herein also includes, pharmaceutically acceptable salts of ciclesonide, epimers of ciclesonide (e.g. [11 ⁇ ,16 ⁇ (S)]-
  • physiologically functional derivative is meant a chemical derivative of ciclesonide having the same physiological function as ciclesonide, for example, by being convertible in the body thereto or by being an active metabolite of ciclesonide.
  • Physiological functional derivatives of ciclesonide which may be mentioned in connection with the invention are for example the 21 -hydroxy derivative of ciclesonide with the chemical name 16 ⁇ , 17-(22R,S)-Cyclohexylmethylendioxy-11 ⁇ ,21 -dihydroxypregna-1 ,4-dien-3,20-dion, 16 ⁇ ,17-(22S)-Cyclo-hexylmethylendioxy-11 ⁇ ,21-dihydroxypregna-1 ,4-dien-3,20-dion and in particular 16 ⁇ , 17-(22R)-Cyclohexylmethylendioxy-11 ⁇ , 21 -dihydroxypregna-1 ,4-dien-3,20-dion.
  • This compound and its preparation are disclosed in WO 9422899.
  • ciclesonide is dispersed in the aqueous medium in form of solid particles.
  • the concentration of ciclesonide of the present invention is preferably from 0.01 % w/w to 1 % w/w, and particularly preferably from 0.02 w/w to 0.5 % w/w, relative to the total amount of the composition.
  • ciclesonide particles that can be used in the present invention may be of any size, they are preferably within the range of 10 nm to 100 ⁇ m, and particularly preferably within the range of 100 nm to 10 ⁇ m.
  • Olopatadine has the chemical name (Z)-11-(3-dimethylaminopropylidene)-6,11-dihydro-dibenz- [b,e]oxepine-2-acetic acid and is disclosed in US 5116863.
  • olopatadine may also be present in form of a pharmaceutically acceptable salt and/or a solvate.
  • Suitable pharmacologically acceptable salts of olopatadine are salts with acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, acetic acid, citric acid, D-gluconic acid, benzoic acid, 2-(4-hydroxybenzoyl)-benzoic acid, butyric acid, sulfosalicylic acid, maleic acid, lauric acid, malic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, embonic acid, stearic acid, toluenesulfonic acid, methanesulfonic acid or 1-hydroxy-2-naphthoic acid, the acids being employed in salt preparation - depending on whether it is a mono- or polybasic acid and depending on which salt is desired - in an equimolar quantitative ratio or one differing therefrom.
  • acids such as, for example, hydrochloric acid, hydrobromic acid,
  • physiologically functional derivative a chemical derivative of olopatadine having the same physiological function as olopatadine, for example, by being convertible in the body thereto or by being an active metabolite of olopatadine.
  • olopatadine is employed as hydrochloride salt of (Z)-11-(3-dimethylaminopropylidene)-6, 11- dihydrodibenz[b,e]oxepine-2-acetic acid.
  • olopatadine will be dissolved in the pharmaceutical compositions according to the invention.
  • the concentration of olopatadine is preferably from 0.1 % w/w to 1.0 % w/w, and particularly preferably from 0.2 % w/w to 0.9 % w/w, relative to the total amount of the composition.
  • Any method for dispersing a water-insoluble substance and/or water-low soluble substance in an aqueous medium may be used for the production of the aqueous pharmaceutical composition according to the invention, a specific example of which is a method that uses a homomixer.
  • antiseptics include benzalkonium chloride
  • pH controlling agents include hydrochloric acid and sodium hydroxide
  • preservatives include potassium sorbate
  • buffers include phosphoric acid and its salt
  • colorants include red dye no. 2
  • smell corrigents include menthol.
  • ciclesonide Due to the unique galenic formulation, ciclesonide rapidly enters the nasal mucosa and has a very long retention time. Therefore, very low doses of ciclesonide and the once daily, maximal twice-daily treatment is necessary to achieve an effective treatment.
  • a low dose of ciclesonide in a hypotonic watery suspension in combination with olopatadine results in a very effective and safe treatment of all symptoms accompanied with allergic rhinitis.
  • a clear advantage of this combination is the rapid onset of action and quick symptom relief without the fear of glucocorticoid like side effects.
  • the present invention relates to a combination of ciclesonide with olopatadine and in which ciclesonide is applied in a pharmaceutical composition as described for ciclesonide in WO 01/28562 or WO 01/28563 and olopatadine is applied in a pharmaceutical formulation according to US 2003/0055102.
  • the invention furthermore relates to a medical product comprising, together, (i) ciclesonide; and (ii) olopatadine as combined preparation for administration to the nasal mucosa.
  • the medical product preferably is for the treatment of allergic rhinitis.
  • the invention also relates to a medical product comprising; together (i) ciclesonide; and
  • the medical product preferably is for the treatment of allergic conjunctivitis.
  • the formulation according to the present invention When given to the nasal mucosa the formulation according to the present invention may be filled into plastic squeeze bottles or plastic or glass bottles, which are fitted with a metering atomising pump and a nasal adapter or with a suitable dropper.
  • the formulation according to the present invention When given to the eye the formulation according to the present invention may be filled into plastic squeeze bottles or plastic or glass bottles, which are fitted with a suitable dropper. Examples
  • Ciclesonide aqueous pharmaceutical compositions containing the components indicated below are prepared by processing with a homomixer. Homomixer processing is performed, e.g., at 6000 rpm for 30 minutes.
  • Ciclesonide 0.05% (w/w)
  • Each 100 mg spray delivered by a nasal applicator delivers 50 ⁇ g of ciclesonide and 444 ⁇ g of olopatadine hydrochloride (equivalent to 400 ⁇ g olopatadine).

Abstract

La présente invention concerne une combinaison de ciclésonide avec de l'olopatadine.
PCT/EP2006/060682 2005-03-15 2006-03-14 Nouvelle combinaison WO2006097458A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66167205P 2005-03-15 2005-03-15
US60/661,672 2005-03-15

Publications (1)

Publication Number Publication Date
WO2006097458A1 true WO2006097458A1 (fr) 2006-09-21

Family

ID=36498810

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/060682 WO2006097458A1 (fr) 2005-03-15 2006-03-14 Nouvelle combinaison

Country Status (1)

Country Link
WO (1) WO2006097458A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007092333A1 (fr) * 2006-02-03 2007-08-16 Hypnion, Inc. Utilisation d'olopatadine pour le traitement des troubles du sommeil
WO2011135585A3 (fr) * 2010-04-28 2012-01-26 Cadila Healthcare Limited Solution pharmaceutique aqueuse de ciclésonide
EP3037094A1 (fr) * 2014-12-23 2016-06-29 Poifa Warszawa SA Composition pharmaceutique ophtalmique
US10668167B2 (en) 2016-06-02 2020-06-02 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
US10772970B2 (en) 2017-12-01 2020-09-15 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001035963A1 (fr) * 1999-11-18 2001-05-25 Alcon Universal Ltd. Utilisation d'un antagoniste h1 et d'un steroide inoffensif dans le traitement des affections oculaires
WO2003002093A1 (fr) * 2001-06-27 2003-01-09 Alcon, Inc. Formulations d'olopatadine a administration topique
WO2004019955A1 (fr) * 2002-08-30 2004-03-11 Altana Pharma Ag Utilisation de la combinaison de ciclesonide et d'antihistaminiques pour le traitement de la rhinite allergique
EP1467762B1 (fr) * 2001-12-05 2006-02-08 Alcon, Inc. Utilisation d'un antagoniste h1 et du rimexolone comme steroide inoffensif pour traiter la rhinite

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001035963A1 (fr) * 1999-11-18 2001-05-25 Alcon Universal Ltd. Utilisation d'un antagoniste h1 et d'un steroide inoffensif dans le traitement des affections oculaires
WO2003002093A1 (fr) * 2001-06-27 2003-01-09 Alcon, Inc. Formulations d'olopatadine a administration topique
EP1467762B1 (fr) * 2001-12-05 2006-02-08 Alcon, Inc. Utilisation d'un antagoniste h1 et du rimexolone comme steroide inoffensif pour traiter la rhinite
WO2004019955A1 (fr) * 2002-08-30 2004-03-11 Altana Pharma Ag Utilisation de la combinaison de ciclesonide et d'antihistaminiques pour le traitement de la rhinite allergique

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007092333A1 (fr) * 2006-02-03 2007-08-16 Hypnion, Inc. Utilisation d'olopatadine pour le traitement des troubles du sommeil
WO2011135585A3 (fr) * 2010-04-28 2012-01-26 Cadila Healthcare Limited Solution pharmaceutique aqueuse de ciclésonide
EP3037094A1 (fr) * 2014-12-23 2016-06-29 Poifa Warszawa SA Composition pharmaceutique ophtalmique
US10668167B2 (en) 2016-06-02 2020-06-02 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
US10772970B2 (en) 2017-12-01 2020-09-15 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof

Similar Documents

Publication Publication Date Title
US8313732B2 (en) Formoterol superfine formulation
US20220241297A1 (en) Use of ciclesonide for the treatment of respiratory diseases
US8486923B2 (en) Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
US20080027034A1 (en) Ciclesonide and Syk Inhibitor Combination and Method of Use Thereof
US20060293293A1 (en) Salmeterol and ciclesonide combination
US20070185067A1 (en) Ciclesonide and glycopyrronium combination
US8088362B2 (en) Salmeterol superfine formulation
CA3181959A1 (fr) Combinaison d'alcaftadine et d'un corticosteroide
WO2006097458A1 (fr) Nouvelle combinaison
US20070134165A1 (en) Use of Ciclesonide for the Treatment of Respiratory Disease in a Smoking Patient

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06725038

Country of ref document: EP

Kind code of ref document: A1

WWW Wipo information: withdrawn in national office

Ref document number: 6725038

Country of ref document: EP